免疫表型及FCSS在骨髓增生异常综合征中的应用

目的：探讨骨髓增生异常综合征（myelodysplastic syndrome,MDS）患者免疫表型特点及预后,以及流式细胞术积分系统（flow cytometric scoring system,FCSS）在MDS中的应用.方法：回顾性分析2006年至2012年根据FAB及WHO标准诊断为MDS的1 12例患者.采用多参数流式细胞术（multiparameter flow cytometry,MFC）研究其免疫表型改变,分别对幼稚细胞群、成熟粒细胞群、单核细胞群及有核红细胞进行分析,并对这些患者进行随访及生存期分析.结果：幼稚细胞群异常表达CD7占20.54％,成熟粒细胞群CD13/CD16结构关系异常占57.14％,单核细胞群CD56异常表达占21.43％,根据FCSS进行分组,各分组之间中位总生存期（mOS）存在显著差异,并且随着FCSS积分的增加,生存期显著缩短.结论：免疫表型异常对MDS的诊断及预后评估有重要意义,FCSS标准作为一种量化的流式细胞术积分系统,可以对MDS的诊断及预后评估起重要作用.

Application of immunophenotyping and FCSS in myelodysplastic syndrome

Objective：To investigate the clinical immunophetyping features and prognosis of myelodysplastic syndrome and discuss the application of FCSS in MDS.Methods：A retrospective analysis was conducted on 112 patients diagnosed with MDS on basis of FAB and WHO criterion.Multiparameter flow cytometry was performed to investigate the immunophetyping features.Results：Abnormal antigen expression was found in the samples,including CD7 ＋ in myeloid blasts（20.54％）,abnormal CD13/CD16 in granulocytes,CD56 ＋ in monocytes.There was significant difference between the abnormal antigen expression and MS.The survival time was significantly shortened,as the increase of FCSS score.Conclusion：FCSS is of guiding significance in diagnosis and prognosis evaluation of MDS.MDS patients can be effectively layered and evaluated by FCSS as a quantitative scoring system.